# ACTIMMUNE in Intermediate Osteopetrosis

> **NCT02666768** · PHASE2 · COMPLETED · sponsor: **Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center** · enrollment: 5 (actual)

## Conditions studied

- Osteopetrosis

## Interventions

- **DRUG:** Interferon gamma-1b

## Key facts

- **NCT ID:** NCT02666768
- **Lead sponsor:** Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-22
- **Primary completion:** 2019-03-11
- **Final completion:** 2019-04-11
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2024-10-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02666768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02666768, "ACTIMMUNE in Intermediate Osteopetrosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02666768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*